Table 2 Univariable and multivariable analysis of factors associated with extended endocrine therapy use.
From: Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivors
Covariate | Univariate model | Multivariate model (n = 488) | ||
|---|---|---|---|---|
OR (95% CI) | P | OR (95% CI) | P | |
Age (years) | 1.06 (1.02, 1.11) | 0.009 | 1.10 (1.04, 1.16) | <0.001 |
non-Hispanic white (ref: other) | 0.57 (0.34, 0.96) | 0.033 | 0.49 (0.28, 0.87) | 0.015 |
Financially not comfortable at baseline (ref: comfortable) | 0.87 (0.60, 1.26) | 0.450 | ||
Education at baseline (ref: Less than college) | 1.44 (0.85, 2.42) | 0.172 | ||
Partnered at baseline (ref: Not partnered) | 2.28 (1.46, 3.54) | <0.001 | ||
Children pre-diagnosis (ref: none) | 1.52 (1.06, 2.20) | 0.025 | ||
Stage | ||||
II vs I | 3.85 (2.56, 5.79) | <0.001 | 2.86 (1.81, 4.51) | <0.001 |
III vs I | 5.45 (2.88, 10.31) | <0.001 | 3.73 (1.87, 7.44) | <0.001 |
HER2 Positive (ref: negative) | 0.99 (0.67, 1.47) | 0.971 | ||
Mastectomy (ref: lumpectomy) | 0.55 (0.37, 0.80) | 0.002 | ||
Receipt of radiation therapy (ref: none) | 1.55 (1.06, 2.27) | 0.023 | ||
Receipt of chemotherapy (ref: none) | 5.17 (3.26, 8.20) | <0.001 | 3.66 (2.16, 6.21) | <0.001 |
